KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Clinical trial NCT04165070 · RECRUITING
Trial details
- NCT number
- NCT04165070
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-19
- Primary completion
- 2032-02-13
- Enrollment
- 450
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.